Two dual therapy cancer models of sEH inhibition combined with either COX-2 inhibition or c-RAF inhibition show robust tumor growth and metastasis inhibition, and in the case of the dual sEH/COX-2 inhibitor (discussed below), both bladder cancers and glioblastomas were found to be inhibited with significantly decreased angiogenesis (Liao et al., 2016b; Li et al., 2017; Wang et al., 2018a). The gene discussed is EPHX2; the disease is urinary bladder carcinoma.